Patents by Inventor Suizhen Lin

Suizhen Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10980850
    Abstract: Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: April 20, 2021
    Assignee: Guangzhou Virotech Phamaceutical Co., Ltd.
    Inventors: Guangmei Yan, Jing Cai, Yuan Lin, Haipeng Zhang, Suizhen Lin, Shoufang Gong, Jun Hu, Xiao Xiao, Kai Li, Jiankai Liang, Yaqian Tan, Wenbo Zhu, Wei Yin
  • Publication number: 20210060035
    Abstract: Disclosed is a use of 5?-androstane-3?,5,6?-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.
    Type: Application
    Filed: December 28, 2018
    Publication date: March 4, 2021
    Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD
    Inventors: Guangmei YAN, Yijun HUANG, Wei YIN, Suizhen LIN
  • Publication number: 20200330483
    Abstract: Disclosed is use of 5?-androst-3?,5,6?-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.
    Type: Application
    Filed: December 28, 2018
    Publication date: October 22, 2020
    Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD
    Inventors: Guangmei YAN, Wei YIN, Longxiang SHENG, Bingzheng LU, Yijun HUANG, Suizhen LIN
  • Publication number: 20200085892
    Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
    Type: Application
    Filed: November 12, 2019
    Publication date: March 19, 2020
    Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD
    Inventors: Guangmei YAN, Xiao XIAO, Jun HU, Kai LI, Jiankai LIANG, Yuan LIN, Haipeng ZHANG, Suizhen LIN
  • Patent number: 10517909
    Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: December 31, 2019
    Assignee: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD
    Inventors: Guangmei Yan, Xiao Xiao, Jun Hu, Kai Li, Jiankai Liang, Yuan Lin, Haipeng Zhang, Suizhen Lin
  • Publication number: 20190183948
    Abstract: This invention belongs to the field of biomedicine and relates to use of Bcl-xL inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that the Bcl-xL inhibitor can be used as an anti-tumor synergist for oncolytic virus. The present invention also relates to a pharmaceutical composition comprising Bcl-xL inhibitor and oncolytic virus, a pharmaceutical kit comprising Bcl-xL inhibitor and oncolytic virus, and use of Bcl-xL inhibitor and oncolytic virus for treating tumors, especially, tumors that are not sensitive to the oncolytic virus.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 20, 2019
    Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.
    Inventors: Guangmei YAN, Yaqian TAN, Yuan LIN, Haipeng ZHANG, Suizhen LIN, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Jing CAI, Wenbo ZHU, Wei YIN
  • Publication number: 20190167641
    Abstract: The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 6, 2019
    Applicant: Guangzhou Virotech Pharmaceutical Co., Ltd.
    Inventors: Guangmei YAN, Haipeng ZHANG, Yuan LIN, Suizhen LIN, Jing CAI, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Yaqian TAN, Wenbo ZHU, Wei YIN
  • Publication number: 20190167737
    Abstract: Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 6, 2019
    Applicant: Guangzhou Virotech Pharmaceutical Co., Ltd.
    Inventors: Guangmei YAN, Jing CAI, Yuan LIN, Haipeng ZHANG, Suizhen LIN, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Yaqian TAN, Wenbo ZHU, Wei YIN
  • Patent number: 9944672
    Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: April 17, 2018
    Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD.
    Inventors: Suizhen Lin, Jingxia Zhang, Xinhua Li
  • Patent number: 9944673
    Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: April 17, 2018
    Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD.
    Inventors: Suizhen Lin, Jingxia Zhang, Xinhua Li
  • Publication number: 20170305957
    Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
    Type: Application
    Filed: May 8, 2017
    Publication date: October 26, 2017
    Inventors: Suizhen LIN, JINGXIA ZHANG, XINHUA Li
  • Publication number: 20170304380
    Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
    Type: Application
    Filed: August 24, 2015
    Publication date: October 26, 2017
    Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.
    Inventors: Guangmei YAN, Xiao XIAO, Jun HU, Kai LI, Jiankai LIANG, Yuan LIN, Haipeng ZHANG, Suizhen LIN
  • Publication number: 20170305958
    Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
    Type: Application
    Filed: May 8, 2017
    Publication date: October 26, 2017
    Inventors: Suizhen LIN, Jingxia ZHANG, Xinhua LI
  • Patent number: 9688716
    Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: June 27, 2017
    Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD.
    Inventors: Suizhen Lin, Jingxia Zhang, Xinhua Li
  • Patent number: 9428539
    Abstract: The present invention discloses compound 2?,3?,5?-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: August 30, 2016
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Jingxia Zhang, Suizhen Lin, Minyu Xie
  • Publication number: 20160039862
    Abstract: The present invention discloses compound 2?,3?,5?-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.
    Type: Application
    Filed: March 28, 2014
    Publication date: February 11, 2016
    Inventors: Jingxia ZHANG, Suizhen LIN, Minyu XIE
  • Publication number: 20150045566
    Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.
    Type: Application
    Filed: April 11, 2012
    Publication date: February 12, 2015
    Inventors: Suizhen Lin, Jingxia Zhang, Xinhua Li